
Novo Nordisk takes over Inversago Pharma Inc.
As competiion for Novo Nordisk A/S’ subcutanously administered blockbuster GLP1-receptor blocker semaglutide is growing, particularly as an obesity...

Gleamer raises €27m in Series B funding round
Gleamer SAS’ financing round was led by Supernova Invest, co-led by Heal Capital and backed by Gleamer’s long-term partners XAnge, Elaia, Bpifrance...

Oxford Biomedica acquires ABL Europe for €15m
Oxford Biomedica PLC, and Institut Mérieux have entered exclusive negotiations for the acquisition of ABL Europe Inc. This move is set to solidify...

Mystery solved: Mysthera Theapeutics launches with $3.5m
Mysthera Therapeutics AG was just founded in Basel, Switzerland by Forty51 Ventures with $3.5m seed capital. Pursuing a first-in-class...

UK invests in biopharma manufacturers
The agency announced that seventeen new projects will receive funding for cutting edge medicine manufacturing, delivered by the Innovate UK...

Resistance blocker of immune checkpoint inhibitors gets patented
DT-9081, Domain Therapeutics’ selective EP4 receptor antagonist, preclinically synergised with PD1-checkpoint blockers and shrinked tumours by...

Pairwise and Bayer collaborate to CRISPR short-stem maize
Following Leaps by Bayer's co-investment in a US$90m Series B financing in Pairwise Plants Services Inc. in 2021,German seed giant Bayer AG has...